Thalidomide--a therapy for the immunological consequences of HIV infection?
The beneficial effects of the teratogenic drug thalidomide on a variety of disorders involving the immune system have been established recently. Comparison of symptoms and immunologic abnormalities of such diseases with the acquired immunodeficiency syndrome, as well as experimentally obtained results suggest that thalidomide may be a useful agent suppressing autoaggressive reactions initiated by the human immunodeficiency virus.
Günzler
V
V
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D001402:B-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013792:Thalidomide / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013792:Thalidomide